Novavax (NVAX) announced the appointment of Charles Newton to its board as an independent director. Newton brings extensive experience in public markets and healthcare investment banking to his role on the Novavax Board of Directors. Newton currently serves as CFO of Lyell Immunopharma, with past leadership experience in healthcare investment banking at Bank of America Merrill Lynch, Credit Suisse and Morgan Stanley.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NVAX:
- Novavax board ‘appreciates support of Shah Capital’
- Confusion surrounds FDA’s delay in granting Novavax vaccine approval, STAT says
- Novavax believes COVID BLA ‘approvable’ upon alignment on details with FDA
- ‘Regulatory Headwinds Set to Bite,’ Says Top Analyst on Novavax Stock (NVAX)
- Novavax asked for new Covid-19 vaccine trial by FDA, WSJ reports